 PHILADELPHIA, May 03, 2022 GLOBE NEWSWIRE -- Passage Bio, Inc. NASDAQ: PASG, a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system CNS disorders, today announced that additional clinical and biomarker data from Cohort 1 in the Imagine-1 study for GM1 gangliosidosis will be presented at the upcoming American Society of Gene and Cell Therapy ASGCT 25th Annual Meeting, which is being held in Washington, D.C. and virtually on May 16-19, 2022. 